EMA Recommends Approval of Three Biosimilars

Article

The agency recommended nine drugs including treatments for diabetes, hepatitis B, and HIV.

The European Medicines Agency (EMA) announced during its November 2016 meeting that the agency’s Committee for Medicinal Products for Human Use (CHMP) was recommending nine drugs for approval. Three of the approved drugs were biosimilars: Lusduna (insulin glargine) for the treatment of diabetes, and Movymia and Terrosa (both containing teriparatide) for the treatment of osteoporosis. Generics Darunavir Mylan (darunavir), for the treatment of HIV-1, and Tadalafil Generics (tadalafil), for the treatment of pulmonary arterial hypertension were also approved.

Marketing authorization approval was also given to Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A; Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B; Fiasp (insulin aspart) for the treatment of diabetes; and Suliqua (insulin glargine/lixisenatide) for the treatment of type 2 diabetes.

Conditional marketing authorization was renewed for Translarna, a treatment for Duchenne muscular dystrophy. CHMP also recommended therapeutic indication extension for Arzerra, Caprelsa, Humira, Nimenrix, and Vimpat.

Source: EMA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
© 2025 MJH Life Sciences

All rights reserved.